论文部分内容阅读
应用斑点杂交技术对３６例卵巢癌石蜡包埋组织进行了Ｃ－ｅｒｂＢ－２和Ｃ－ｍｙｃ原癌基因扩增的研究。结果表明，Ｃ－ｅｒｂＢ－２原癌基因扩增者１２例，扩增率为３３％，扩增集中于组织学Ⅲ级；Ｃ－ｍｙｃ原癌基因扩增者１０例，扩增率为２７．８％，扩增与组织学分级无关。Ｃ－ｅｒｂＢ－２扩增与ＤＮＡ倍体水平有关，与临床分期无关：Ｃ－ｍｙｃ扩增与倍体水平无关且多见于临床晚期。提示Ｃ－ｅｒｂＢ－２原癌基因扩增可用于判断卵巢癌的恶性程度，Ｃ－ｍｙｃ扩增有助于卵巢癌的临床分期。
The study of C-erbB-2 and C-myc oncogene amplification in 36 cases of ovarian cancer paraffin-embedded tissues by dot blot hybridization. The results showed that in 12 cases of C-erbB-2 proto-oncogene amplification, the amplification rate was 33%, and the amplification focused on the histological grade Ⅲ. The amplification of C-myc proto-oncogene was 10 .8%, amplification and histological grade has nothing to do. C-erbB-2 amplification and DNA ploidy level, and clinical stage has nothing to do: C-myc amplification has nothing to do with the ploidy level and more common in clinical late. It is suggested that the amplification of C-erbB-2 proto-oncogene can be used to judge the malignant degree of ovarian cancer. C-myc amplification contributes to the clinical staging of ovarian cancer.